![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
In chronic obstructive pulmonary disease (COPD) health-related quality-of-life (HRQoL)/health status improvement is included among the management goals. This can be achieved, among other measures, with inhaled therapies, which, in this disease, are used alone or combined in a step-up approach based on disease severity. As COPD is a chronic disease, the long-term effects of inhaled therapies on various disease outcome measures, such as symptoms, lung function, morbidity or HRQoL, are more relevant for accessing clinical efficacy. This review discusses briefly the HRQoL assessment tools in COPD and analyses the effects of inhaled therapies on HRQoL in stable COPD.
Financial & competing interests disclosure
The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.